Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLIC-1901 CAR T-cells for relapsed/refractory CD19-positive ALL and NHL (DAN-CART 1901)
2021-006556-14Phase 2Active
- Sponsor
- Rigshospitalet
- Start
- Apr 2022
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of DK-CLIC-1901 in acute lymphoblastic leukemia (ALL), B-cell non-Hodgkin lymphoma (B-NHL) and non-Hodgkin lymphoma (NHL), sponsored by Rigshospitalet. Primary endpoint: Cytokine release syndrome incidence and severity. Started Apr 2022; status: active.
02
Drugs
DK-CLIC-1901
03
Conditions
acute lymphoblastic leukemia (ALL)B-cell non-Hodgkin lymphoma (B-NHL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on 2021-006556-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006556-14.